Anti-emetics for cancer chemotherapy-induced emesis potential of alternative delivery systems

Drugs

Volumn 61, Issue 11, 2001, Pages 1553-1562

  Kraut, L ^a   Fauser, A A ^a  

^a Clinic for Bone Marrow Transplantation and Hematology/Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE; FENTANYL; GRANISETRON; LERISETRON; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; SCOPOLAMINE; TETRAHYDROCANNABINOL;

CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; GENE THERAPY; HUMAN; MULTICENTER STUDY; NONHUMAN; PATIENT COMPLIANCE; RAT; REVIEW; TECHNIQUE;

EID: 0034812947     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161110-00003     Document Type: Review

References (66)

1. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies
2. Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice
3. On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993
4. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
5. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development
6. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery
7. Guidelines for anti-emetic therapy: Acute emesis
8. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study
9. Single-dose granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly-emetogenic cisplatin-based chemotherapy
10. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy
11. Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer
12. Randomized, double blind, dose response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy
13. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting
14. Evaluation of the anti-emetic effectiveness of two drug formulations of ondansetron in combined chemotherapy for children with malignant tumors
15. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy
16. Cost-effective use of antiemetics
17. 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
18. Alternative routes of drug administration - Advantages and disadvantages
19. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: A double blind comparative study with ondansetron tablets
20. Ondansetron suppository: A randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea
21. Ondansetron suppository: An effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy
22. Transdermal delivery systems
23. Transdermal drug delivery: Useful paradigms
24. Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery
25. Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting
26. Prevention of nausea and vomiting with transdermal hyoscine in adults after middle ear surgery during general anaesthesia
27. Transdermal scopolamine for prevention of postoperative nausea and vomiting. No clinical relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients
28. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: First clinical report
29. Comparative study 'in vitro' of transdermal absorption of a series of antiemetic drugs
30. A comparative in vitro study of transdermal absorption of antiemetics
31. 3 antagonist, in patients with cancer
32. Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects
33. Transdermal delivery of steroids
34. Inhaled and nasal corticosteroids: Factors affecting the risks of sytemic adverse effects
35. Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone
36. Intranasal drug delivery
37. The nasal delivery of systemic drugs
38. Recent trends in drug delivery systems: Intranasal drug delivery
39. Peptide hormones: Review of current and emerging uses by nasal delivery
40. Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers
41. Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients
42. Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study
43. Intranasal metoclopramide
44. A double-blind, placebo-controlled evaluation of intranasal metoclopramide in the prevention of postoperative nausea and vomiting
45. Nasal absorption of ondansetron in rats: An alternative route of drug delivery
46. Drug-delivery products and the Zydis fast-dissolving dosage form
47. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: A multicenter, double-masked study
48. Comparison of buccal and oral prochlorperazine in the treatment of dizziness associated with nausea and/or vomiting
49. Review of the transmucosal drug delivery
50. Targeted delivery of inhaled drugs: Current challenges and future goals
51. Inhalable drugs for systemic therapy
52. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis
53. Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol
54. Randomized double-blind comparison of delta-9-THC and marijuana as chemotherapy antiemetics
55. Phase I trial of levonantradol in chemotherapy-induced emesis
56. Inhalation marijuana as an antiemetic for cancer chemotherapy
57. Blood Cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana
58. Marijuana and medicine: Assessing the science base: A summary of the 1999 Institute of Medicine report
59. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enbancement, vesicle penetration, and transdermal drug delivery
60. Usefulness of liposomes as an intranasal dosage formulation for topical drug application
61. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to faciliate outpatient administration of high-dose chemotherapy
62. Transdermal scopolamine-induced neurologic deficits in patients with cancer
63. The development of delivery agents that faciliate the oral absorption of macromolecular drugs
64. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist
65. Novel approaches to the treatment of nausea and vomiting
66. A new class of antiemetics: The NK-1 receptor antagonists